A Special Protocol Assessment Agreement Reached with the U.S. Food and Drug Administration for Phase 3 clinical trial of Sovateltide for the treatment of acute cerebral ischemic stroke patients
02 oct. 2023 07h25 HE
|
Pharmazz, Inc.
Special Protocol Assessment Agreement Reached Between Pharmazz, Inc. and the U.S. Food and Drug Administration for Phase 3 Clinical Trial of Sovateltide